OncRef

Clinical Trial: NCT03611738

Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 1

Lead Sponsor:H. Lee Moffitt Cancer Center and Research Institute
Information Provided By:H. Lee Moffitt Cancer Center and Research Institute
Last Update Posted:2026-05-15

Study Overview

Brief Summary

The main purpose of this study is to find out what effects (good and bad) ceritinib (Zykadia®) used in combination with docetaxel (Taxotere®) will have on participants and their cancer. The results will help to determine the best safe dose of the combination of the medications Ceritinib (Zykadia®) and docetaxel (Taxotere®) and to find out if this combination of drugs will help people that have this type of Non-small Cell Lung Cancer (NSCLC).

Official Title

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Conditions

Non-small Cell Lung Cancer, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Lung Cancer Stage IIIB, Stage IV Non-small Cell Lung Cancer, EGFR Negative Non-Small Cell Lung Cancer

Intervention / Treatment

  • Drug: Ceritinib
  • Drug: Docetaxel

Other Study ID Numbers

  • MCC-19656

Start Date (Actual)

2019-02-01

Primary Completion Date (Actual)

2025-04-28

Study Completion Date (Estimated)

2027-03

Enrollment (Actual)

21

Study Type

Interventional

Phase

Phase 1